Dr. Kiran Naqvi, MD

Dr. Naqvi practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Naqvi's NPI, 1407881592, was assigned on July 11, 2006. Dr. Naqvi graduated from Dow University of Health Sciences in 2001. Dr. Naqvi's California license number on file is C143761.

Dr. Naqvi's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Naqvi's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naqvi practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Naqvi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Naqvi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Naqvi's licenses on file in 4 states: California, Texas, Massachusetts and Illinois.

Dmand AI lists chronic anemia, lymphoma and multiple myeloma among the conditions Dr. Naqvi treats.

CMS data shows 478 Medicare services from Dr. Naqvi across 5 procedure codes in 2024, for 69 Medicare patients. Medicare paid $53,129 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 69 Medicare patients who saw Dr. Naqvi in 2024. The largest group is 75 to 84, with 32 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 39% are also on Medicaid. Their average risk score is 3.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naqvi's median patient age at 64, with 51% women.

In 2024, Dr. Naqvi wrote 561 Medicare Part D claims for 45 patients. 79% of them were for generic drugs. CMS names the drug for 383 of them, across 13 drugs with 11 or more claims each, at $724,987 in total drug cost. In 2023, CMS named 109 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Naqvi for performance year 2024, reported through an alternative payment model (APM). Dr. Naqvi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Naqvi as offering telehealth.

Dmand AI links 89 papers to Dr. Naqvi, published from 2011 to 2025. 2019 was the busiest year, with 19. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Myelodysplastic Syndromes. Dr. Naqvi has published most often in Am J Hematol. Dr. Naqvi's most frequent co-authors are Hagop M. Kantarjian, MD, Tapan M. Kadia, MD and Gautam Borthakur, MD.

Dmand AI links Dr. Naqvi to 6 clinical trials, 2 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. M.D. Anderson Cancer Center sponsors the most, 3.

CMS Open Payments shows 29 general payments to Dr. Naqvi from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Novartis Pharmaceuticals Corporation paid the most, $3,537. It also lists 1 research payment totaling $480 in 2023.

Dr. Naqvi graduated from Dow University of Health Sciences in 2001.

Dr. Naqvi is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.